局灶冷却治疗耐药性癫痫:综述
本文综述局灶冷却治疗耐药性癫痫(DRE)的现有证据,指出冷却可安全有效地终止癫痫样放电、发作及癫痫持续状态,但除随机临床试验外尚未准备用于人类,并概述装置设计与冷却参数等技术挑战。
要点
- 局灶冷却可能安全有效地治疗耐药性癫痫,但除随机临床试验外尚未准备用于人类。
- 冷却可跨物种(包括人类)安全终止癫痫样放电、发作及癫痫持续状态。
- 局灶冷却面临最佳装置设计与冷却参数等技术挑战。
核心结论
- 冷却已被证明是耐药性癫痫可能安全有效的治疗方式,但除随机临床试验外尚未准备用于人类。
研究设计与样本
- 本文为综述,呈现支持局灶冷却治疗癫痫的最新证据,并概述人类局灶冷却的技术挑战,包括最佳装置设计与冷却参数。
主要发现
- 大量研究支持局灶冷却作为癫痫长期治疗可能有效的前提。
- 局灶冷却的潜在优势有三:跨物种(包括人类)安全终止癫痫样放电、发作及癫痫持续状态。
局限性
- 局灶冷却除随机临床试验外尚未准备用于人类。
- 人类局灶冷却存在技术挑战,包括最佳装置设计与冷却参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epilepsy affects at least 1.2% of the population, with one-third of cases considered to be drug-resistant epilepsy (DRE). For these cases, focal cooling therapy may be a potential avenue for treatment, offering hope to people with DRE for freedom from seizure. The therapy leverages neuroscience and engineering principles to deliver a reversible treatment unhindered by pharmacology. OBSERVATIONS: Analogous to (but safer than) the use of global cooling in postcardiac arrest and neonatal ischemic injury, extensive research supports the premise that focal cooling as a long-term treatment for epilepsy could be effective. The potential advantages of focal cooling are trifold: stopping epileptiform discharges, seizures, and status epilepticus safely across species (including humans). CONCLUSIONS AND RELEVANCE: This Review presents the most current evidence supporting focal cooling in epilepsy. Cooling has been demonstrated as a potentially safe and effective treatment modality for DRE, although it is not yet ready for use in humans outside of randomized clinical trials. The Review will also offer a brief overview of the technical challenges related to focal cooling in humans, including the optimal device design and cooling parameters.
引用
- Niesvizky-Kogan I, Bass M, Goldenholz SR, et al. Focal Cooling for Drug-Resistant Epilepsy: A Review. JAMA Neurol. 2022. PMID: 35877102. doi:10.1001/jamaneurol.2022.1936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。